Get started
ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)

ABBVIE INC CEDEAR EA 10 REP 1 COM(USD)

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

ABBVD trade ideas

ABBV ABBV is a very high quality stock. It never missed an earnings estimate. Accordingly, my homebrew stock valuation system gives it pretty high scores quality-wise. "val2_k": 5, "val2_q": 8, "qual2_k": 60, "qual2_q": 51, "qual3_k": 59 TA wise, It does seem like ABBV is finishing wave 2 and starts making into 3 of (5) of III. Lots of long term potential for this stock. Though it seems like wave 2 ended at exactly 50% of wave 1, historically, this stocks has shown that wave 2 can retrace upto 76.4% of wave 1. In short, ABBV can find short term low anywhere from 93 to 98 before mooning. Long term target for wave (5) of III is estimated at $145. A nice 45% potential.
NYSE:ABBVLong
by SharpCharts
"Trade what you see not what you think" Bullish SentimentInterest in this market ABBV stock- Strong area of support that rallied up to the $125s which clearly shows institutional interest within the 94-98 zone. 1-3 risk to reward whilst still keeping an eye on 85s Reason for opposing catalyst Retail Investors had all the there chips in hoping for accelerated approval for the drug Rova-T (Drug) which they forked out just shy of $6 billion for Stemcentrx, (Defeating the purpose of the acquisition) Risk management Cut losses quickly Wait till price action breaches more into the level to buy cheaper
NYSE:ABBVLong
by AshirDanville
Abbvie Inc. Head and Shoulders Pattern = Bullish Trend, NEW ATH!Dear Viewers, Welcome to my First Forex Technical Analysis. Let´s get straight to the point, NYSE:ABBV is going through a very nice shaped Head and Shoulder Pattern. For now, as we only have the left shoulder, we can´t predict how high the head will be, or how low the correction after this H&S pattern will go, because the size of the Head and Shoulders structure holds a direct relationship with the potential target for the trade. Therefore, it is paramount to understand how to measure the size of the H&S pattern. To do so, you need to take the distance between the tip of the head and the neck line. This will yield the size of the head and shoulders pattern. We will be doing this once we have a new All Time High from NYSE:ABBV . Once we have what we want, we will be able to apply this length downwards, starting from the initial breakout through the neck line. This is the price move you should expect when trading the Head and Shoulders setup. In other words, the expected price move after the H&S pattern equals to the size of the pattern. This is often referred to by chart technicians as a measured move . FOR THE NEWBIES: The Head and Shoulders pattern appears during a bullish trend and it implies that the existing bullish tendency is likely to be reversed. Conclusion The Head and Shoulders pattern is one of the most reliable chart patterns in Forex. It forms during a bullish trend and has the potential to reverse the uptrend. The name of the Head and Shoulders pattern comes from its visual structure – two tops with a higher top in between. The H&S pattern consists of three tops: The first top should be found in the context of a bullish trend. The second top should be higher than the first top. The third top should be lower than the second top and should be approximately on the same level as the first top. Let´s keep an eye open on this chart together and i´ll update it as soon as we have reached a new A.T.H. and when we have a Head shape. Feel free to leave a comment, to like this TA and of course to follow me if you want to be kept updated ! Raw_Blitz out.
NYSE:ABBVLong
by TjerkPieksma
Dividends + Stock-Repurchase = All-Time High?You can hardly believe it! Humira runs like a clock and allows the Biopharma Group a historic increase in its dividends. At the same time, there is also a new share buyback program! As a result, AbbVie is increasingly emancipating itself and becoming a true global player in the biopharmaceutical business. Humira continues to set the direction. AbbVie Inc. is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The American company AbbVie in 2017 demonstrated worldwide net revenues up 10.1% year-over-year on a GAAP basis ($28.2 billion). Humira increased its revenue in 2017 by 14.6% and reached the level of 18.4 billion US dollars. This makes the blockbuster responsible for 60% of the turnover of the entire AbbVie concern. It is worth to point out that Humira is today the world's best selling drug. What has happened lately? AbbVie has pushed its dividend payments even higher. On February 15, 2018 the company announced an increase to its quarterly dividend. The board of directors of AbbVie increased the company's quarterly cash dividend to $0.96 per share. The dividend the company pays to its shareholders increases by 35 percent compared to the previous year. The cash dividend will be paid to stockholders on May 15, 2018. Along with the news of a dividend increase, AbbVie announced that its board of directors has authorized a new $10 billion stock-repurchase program. What do the analysts say? Based on 11 analysts offering 12 month price targets for ABBV in the last 3 months: The average price target of $133.82 The maximum price target of $157.00 The lowest price target of $95.00 Today ABBV’s stock price is about 120.48 US-Dollar a share. Fundamental Data: P/E ratio: 35.64 / Sales growth: 10.06% / Profit growth: -10.82% / Dividends: $2.63/2.23%(Source: teletrader). What do the technical analysis methods I use say? Oscillator: The RSI of AbbVie is around 60. In this particular case, the 60 level may be viewed as a potential area for a bearish reversal. Price Indicator: The price is above the 200 day moving average - trend is up. Trend indicator: The MACD is currently in the negative zone but is moving up. That could indicate further higher prices. The risk management tool used here is the own-developed “Traffic Signals System” (TSS) and is preferably used in analyzes by Ritschy Dobetsberger. The black line in the chart: the starting price of the idea is 120.48 US-Dollar. The red line in the chart: The stop loss is set at 110 US-Dollar (-8.70% risk from the start of the idea). Conclusion: AbbVie announced a 35% increase in its quarterly dividend and a new share repurchase program worth approximately $ 10 billion. Humira continues to set the direction. As a result, AbbVie continues to emancipate itself and become a true global player in the biopharmaceutical business, enabling higher dividends and share buybacks! Is this a good time to buy AbbVie? This could be a good chance to establish a position trade, because the all-time high is within striking distance! Parameters of the Idea - Start of the idea: $120.48 Recent stock price: $120.48 (+0,00% from the starting price) Stop-Loss of the idea: $110 (-8,70% from the starting price) Take Profit of the idea: $157 (highest target price) This idea has been running since February 21, 2018. Disclosure: "The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such. You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas."
NYSE:ABBVLong
by Ritschy